MNMD
Definium Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$20.69
+0.44%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
Key dataAug 12, 2026
Open$47.51
From 52W high−57.30%
Volume7.63M
Market cap$1.85B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataAug 12, 2026
Open
$47.51
From 52W high
−57.30%
Volume
7.63M
Market cap
$1.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
P/E (TTM)
—
RSI (14)
50.9
MomentumView details →
1D Return
+0.44%
YTD Return
+219.57%
SummaryUpdated Jun 1, 2026
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Vancouver, Canada. The company went public in 2016 and focuses on developing novel therapeutic treatments for brain health disorders including psychiatry, addiction, pain, and neurology. MindMed is at the forefront of psychedelic medicine research, developing treatments based on compounds like LSD and MDMA that have shown promise in addressing mental health conditions that affect millions of people worldwide.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might be used as supervised treatments, with public comments open until October 5.5d agoDefinium Therapeutics reported that its LSD-based therapy DT120 eased anxiety in a second late-stage trial, with patients on a 100-microgram dose showing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo.6d agoDefinium Therapeutics announced six poster presentations at Psych Congress 2026, taking place September 15-19 in New Orleans, covering topline Phase 3 data from the Emerge and Voyage trials of DT120 Orally Disintegrating Tablet in major depressive disorder and generalized anxiety disorder.10d ago